UroGen Pharma Ltd.

Healthcare · Biotechnology · United States

Last price 33.48 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.64B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocal...